RedHill Expands its P-II/III Study Evaluating Yeliva (opaganib) Against COVID-19 in Italy and UK

 RedHill Expands its P-II/III Study Evaluating Yeliva (opaganib) Against COVID-19 in Italy and UK

RedHill Biopharma’s Talicia Received the US FDA’s Approval for H. pylori in Adults

Shots:

  • RedHill has submitted CTA to the MHRA and AIFA for a P-II/III study evaluating opaganib vs PBO along with SOC in patients hospitalized with severe COVID-19. The P-II/III study will enroll 270 subjects in a ratio (1:1) with severe COVID-19 pneumonia requiring hospitalization and treatment with supplemental oxygen
  • The company plans to conduct the study in 40+ clinical sites across Russia, Italy, the UK, and additional countries with 1EPs as the proportion of patients requiring intubation and mechanical ventilation by Day 14
  • The study follows the ongoing P-IIa study assessing Opaganib in the US and will enroll 40 patients with severe COVID-19 pneumonia requiring hospitalization and supplemental oxygen. Additionally, the company reported the encouraging preliminary findings of the therapy from six COVID-19 patients requiring high-flow supplemental oxygen in Israel under compassionate use

Click here to read full press release/ article | Ref: Buinesswire | Image: RedHill

Related News: RedHill Biopharma Reports the Submission of CTA for P-II/III Study Evaluating Opaganib Against COVID-19 in Russia

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post